AC
Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
$2.01 +4.42% (+$0.08)
1M -15.91%
Market Cap $79.2M
P/E Ratio -
Div. Yield -
ROE 70.14%
Bulios Fair Price
$1.3
35.3% downside
Current Price
$2.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ACRV is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.91x
P/FCF N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 12.93%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 74.91%
ROIC 88.28%
Debt
100 /100
Low Current ratio 7.99x
Debt/Equity 0.02x
Net debt/EBITDA N/A
Stability
10 /100
Unstable EPS volatility 62.28%
Profitable years 0
Beta 1.93x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ACRV
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Peter Blume-Jensen
Employees
75
Headquarters
Watertown
Upcoming events
12 NOV
Earnings
Upcoming earnings report